Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9492423B2 · kind B2 · utility
1Cited by
46References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2011 |
| Grant date | Nov 15, 2016 |
| Priority date | — |
| Expiry date | Sep 13, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.